Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2991321rdf:typepubmed:Citationlld:pubmed
pubmed-article:2991321lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2991321lifeskim:mentionsumls-concept:C0017689lld:lifeskim
pubmed-article:2991321lifeskim:mentionsumls-concept:C0030274lld:lifeskim
pubmed-article:2991321lifeskim:mentionsumls-concept:C0061355lld:lifeskim
pubmed-article:2991321lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:2991321lifeskim:mentionsumls-concept:C0376315lld:lifeskim
pubmed-article:2991321pubmed:issue3lld:pubmed
pubmed-article:2991321pubmed:dateCreated1985-9-16lld:pubmed
pubmed-article:2991321pubmed:abstractTextThe structure of human preproglucagon, as deduced from nucleotide sequencing of the preproglucagon gene, contains two glucagon-like peptides (GLP-1 and GLP-2) in the portion C-terminal to glucagon. A rabbit antiserum was raised against synthetic GLP-1-(1-19) which had 20% cross-reactivity with synthetic GLP-1 and des-Gly37-GLP-1 amide, two possible forms of the GLP-1 whole molecule, but no significant cross-reactivity with glucagon or other pancreatic peptides. Immunocytochemistry revealed that the distribution of GLP-1-(1-19) immunoreactivity followed that of glucagon-like immunoreactivity in the normal human pancreas and in two human glucagon-secreting pancreatic tumors. Chromatography of human pancreas extracts on Sephadex G-50 gave peaks of cross-reactivity at Kav values of 0.06-0.16, 0.34-0.39, 0.54-0.58 (the elution position of synthetic GLP-1), and 0.64-0.70. The concentration of immunoreactivity in the Kav 0.54-0.58 peak measured by RIA using GLP-1 or des-Gly37-GLP-1 amide as standard was 94 +/- 7 pmol/g (mean +/- SEM), while the total pancreatic glucagon content was 4.8 +/- 0.8 nmol/g. One extract of a human glucagon-secreting pancreatic tumor contained a prominent peak of GLP-1-(1-19) peptide cross-reactivity with properties identical to those of GLP-1 or des-Gly37-GLP-1 amide on gel filtration and reverse phase high pressure liquid chromatography, but another tumor contained a preponderance of cross-reactive forms of greater molecular size. Pretreatment plasma from three patients with radiological and biochemical evidence of glucagon-secreting tumors contained a peak of cross-reactivity with the chromatographic properties of intact GLP-1. The low concentrations of intact GLP-1 in normal pancreas compared with pancreatic glucagon concentrations suggest that the majority of the proglucagon is cleaved in a manner that does not produce GLP-1, as defined by its delimiting pairs of basic amino acid residues.lld:pubmed
pubmed-article:2991321pubmed:languageenglld:pubmed
pubmed-article:2991321pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2991321pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2991321pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2991321pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2991321pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2991321pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2991321pubmed:statusMEDLINElld:pubmed
pubmed-article:2991321pubmed:monthSeplld:pubmed
pubmed-article:2991321pubmed:issn0021-972Xlld:pubmed
pubmed-article:2991321pubmed:authorpubmed-author:PolakJ MJMlld:pubmed
pubmed-article:2991321pubmed:authorpubmed-author:BloomS RSRlld:pubmed
pubmed-article:2991321pubmed:authorpubmed-author:BishopA EAElld:pubmed
pubmed-article:2991321pubmed:authorpubmed-author:GhiglioneMMlld:pubmed
pubmed-article:2991321pubmed:authorpubmed-author:UttenthalL...lld:pubmed
pubmed-article:2991321pubmed:authorpubmed-author:GeorgeS KSKlld:pubmed
pubmed-article:2991321pubmed:issnTypePrintlld:pubmed
pubmed-article:2991321pubmed:volume61lld:pubmed
pubmed-article:2991321pubmed:ownerNLMlld:pubmed
pubmed-article:2991321pubmed:authorsCompleteYlld:pubmed
pubmed-article:2991321pubmed:pagination472-9lld:pubmed
pubmed-article:2991321pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:meshHeadingpubmed-meshheading:2991321-...lld:pubmed
pubmed-article:2991321pubmed:year1985lld:pubmed
pubmed-article:2991321pubmed:articleTitleMolecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas.lld:pubmed
pubmed-article:2991321pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2991321pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2991321lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2991321lld:pubmed